IP Library › Granted Patent US 12,245,803
Granted Patent B2
US 12,245,803 · App. 18/647,807 · Granted Mar 11, 2025

Systems and methods for therapeutic nasal treatment using handheld device

Inventor: David Townley (Clare, IE)
Assignee: Neurent Medical Limited
A61B18/148A61B2018/00327A61B2018/00434A61B2018/00583A61B2018/1467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,245,803
App. No.
18/647,807
Granted
Mar 11, 2025
Kind
B2
Abstract

The invention generally relates to systems and methods for improving sleep by treating at least one of rhinitis, congestion, and/or rhinorrhea to thereby reduce or eliminate symptoms associated therewith, including, but not limited to, nasal congestion, coughing, sneezing, and nasal or throat irritation and itching.

Claims (38)

1. A method for improving a patient's sleep by treating at least one of rhinitis, congestion, and rhinorrhea within a sino-nasal cavity of a patient, the method comprising:

advancing a multi-electrode end effector into the sino-nasal cavity of the patient, the multi-electrode end effector being operably associated with a shaft of a treatment device and configured for delivering energy to one or more target sites within the sino-nasal cavity of the patient, the multi-electrode end effector comprising a first electrode that is spaced apart from a separate and distinct second electrode along a length of the multi-electrode end effector, wherein each of the first and second electrodes comprises an active state and an inactive state and comprises a respective location on the multi-electrode end effector, and wherein each of the first and second electrodes extends beyond a surface of the shaft and are oriented at an angle relative to the shaft for the delivery of RF energy, wherein:

the first electrode is exposed from a surface of the multi-electrode end effector and is positioned at a separate and discrete portion thereon, the first electrode extending in a first outward direction relative to a longitudinal axis of the shaft to interact with anatomy at a first location within the nasal cavity; and

the second electrode is exposed from a surface of the multi-electrode end effector and is positioned at a separate and discrete portion thereon, the second electrode extending in a second outward direction relative to a longitudinal axis of the shaft to interact with anatomy at a second location within the nasal cavity; and

delivering energy, via the first and second electrodes, to one or more target sites within a sino-nasal cavity of the patient to disrupt multiple neural signals to, and/or result in local hypoxia of, mucus producing and/or mucosal engorgement elements, thereby reducing production of mucus and/or mucosal engorgement within a nose of the patient and reducing or eliminating one or more symptoms associated with at least one of rhinitis, congestion, and rhinorrhea to improve nasal breathability of the patient.

2. The method of claim 1 , wherein the multi-electrode end effector comprises at least four electrodes.

3. The method of claim 1 , wherein radiofrequency (RF) energy is delivered from the first and second electrodes to tissue at the one or more target sites and is controlled via a console unit operably associated with the treatment device and multi-electrode end effector.

4. The method of claim 3 , wherein the console unit is operably coupled to an energy generator configured to generate RF energy to be delivered by the first and second electrodes.

5. The method of claim 4 , wherein the RF energy comprises at least bipolar RF energy.

6. The method of claim 3 , wherein the console unit is configured to receive feedback from at least one temperature sensor arranged relative to the first and second electrodes and configured to sense temperature at an interface between tissue and the first and second electrodes, wherein the console unit is configured to control energy output from the first and second electrodes based, at least in part, on the feedback in order to maintain a predetermined temperature of tissue at the one or more target sites.

7. The method of claim 6 , wherein the console unit is configured to receive one or more temperature readings from the at least one temperature sensor and process the readings to determine a level of RF energy to be delivered by the first and second electrodes that is sufficient to maintain a temperature of tissue at the one or more target sites below a predetermined threshold.

8. The method of claim 7 , wherein the console unit is configured to monitor temperature of tissue at the one or more target sites during delivery of RF energy thereto based on temperature readings from the at least one temperature sensor and further monitor an elapsed time during delivery of RF energy to tissue at the one or more target sites.

9. The method of claim 7 , wherein the console unit is configured to provide, via a display, feedback information to an operator during each treatment application, wherein said feedback information comprises at least an elapsed time during delivery of RF energy to tissue at the one or more target sites.

10. The method of claim 9 , wherein the display is a touchscreen monitor.

11. The method of claim 7 , wherein the console unit comprises a hardware processor coupled to non-transitory, computer-readable memory containing instructions executable by the processor to cause the console unit to automatically control and adjust RF energy output from the first and second electrodes based, at least in part, on a predetermined elapsed time period and a predetermined threshold maximum temperature during delivery of RF energy to ensure that application of said RF energy results in the desired effect of reduced engorgement of the tissue at the target site for a given treatment application.

12. The method of claim 11 , wherein the predetermined threshold maximum temperature is less than 90° C.

13. The method of claim 11 , wherein the predetermined threshold maximum temperature is greater than 37° C. and less than 90° C.

14. The method of claim 11 , the predetermined elapsed time period is from about 1 second to about 20 seconds.

15. The method of claim 14 , wherein the predetermined elapsed time period is from about 10 seconds to about 12 seconds.

16. A method for improving a patient's sleep by treating at least one of rhinitis, congestion, and rhinorrhea within a sino-nasal cavity of a patient, the method comprising:

advancing a multi-electrode end effector into the sino-nasal cavity of the patient, the multi-electrode end effector being operably associated with a shaft of a treatment device and configured for delivering energy to one or more target sites within the sino-nasal cavity of the patient, the multi-electrode end effector comprising a first electrode that is spaced apart from a separate and distinct second electrode along a length of the multi-electrode end effector, wherein each of the first and second electrodes comprises an active state and an inactive state and comprises a respective location on the multi-electrode end effector, and wherein each of the first and second electrodes extends beyond a surface of the shaft and are oriented at an angle less than 90 degrees relative to the shaft for the delivery of RF energy, wherein:

the first electrode is exposed from a surface of the multi-electrode end effector and is positioned at a separate and discrete portion thereon, the first electrode extending in a first outward direction relative to a longitudinal axis of the shaft to interact with anatomy at a first location within the nasal cavity; and

the second electrode is exposed from a surface of the multi-electrode end effector and is positioned at a separate and discrete portion thereon, the second electrode extending in a second outward direction relative to a longitudinal axis of the shaft to interact with anatomy at a second location within the nasal cavity; and

delivering energy, via the first and second electrodes, to one or more target sites within a sino-nasal cavity of the patient to disrupt multiple neural signals to, and/or result in local hypoxia of, mucus producing and/or mucosal engorgement elements, thereby reducing production of mucus and/or mucosal engorgement within a nose of the patient and reducing or eliminating one or more symptoms associated with at least one of rhinitis, congestion, and rhinorrhea to improve nasal breathability of the patient.

17. The method of claim 16 , wherein the multi-electrode end effector comprises at least four electrodes.

18. The method of claim 16 , wherein radiofrequency (RF) energy is delivered from the first and second electrodes to tissue at the one or more target sites and is controlled via a console unit operably associated with the treatment device and multi-electrode end effector.

19. The method of claim 18 , wherein the console unit is operably coupled to an energy generator configured to generate RF energy to be delivered by the first and second electrodes.

20. The method of claim 19 , wherein the RF energy comprises at least bipolar RF energy.

21. The method of claim 18 , wherein the console unit is configured to receive feedback from at least one temperature sensor arranged relative to the first and second electrodes and configured to sense temperature at an interface between tissue and the first and second electrodes, wherein the console unit is configured to control energy output from the first and second electrodes based, at least in part, on the feedback in order to maintain a predetermined temperature of tissue at the one or more target sites.

22. The method of claim 21 , wherein the console unit is configured to receive one or more temperature readings from the at least one temperature sensor and process the readings to determine a level of RF energy to be delivered by the first and second electrodes that is sufficient to maintain a temperature of tissue at the one or more target sites below a predetermined threshold.

23. The method of claim 22 , wherein the console unit is configured to monitor temperature of tissue at the one or more target sites during delivery of RF energy thereto based on temperature readings from the at least one temperature sensor and further monitor an elapsed time during delivery of RF energy to tissue at the one or more target sites.

24. The method of claim 22 , wherein the console unit is configured to provide, via a display, feedback information to an operator during each treatment application, wherein said feedback information comprises at least an elapsed time during delivery of RF energy to tissue at the one or more target sites.

25. The method of claim 24 , wherein the display is a touchscreen monitor.

26. The method of claim 22 , wherein the console unit comprises a hardware processor coupled to non-transitory, computer-readable memory containing instructions executable by the processor to cause the console unit to automatically control and adjust RF energy output from the first and second electrodes based, at least in part, on a predetermined elapsed time period and a predetermined threshold maximum temperature during delivery of RF energy to ensure that application of said RF energy results in the desired effect of reduced engorgement of the tissue at the target site for a given treatment application.

27. The method of claim 26 , wherein the predetermined threshold maximum temperature is less than 90° C.

28. The method of claim 26 , wherein the predetermined threshold maximum temperature is greater than 37° C. and less than 90° C.

29. The method of claim 26 , the predetermined elapsed time period is from about 1 second to about 20 seconds.

30. The method of claim 29 , wherein the predetermined elapsed time period is from about 10 seconds to about 12 seconds.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2024
From: NEURENT MEDICAL LIMITED
To: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L.
Reel/Frame 068942/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: TOWNLEY, DAVID
To: NEURENT MEDICAL LIMITED
Reel/Frame 067828/0790 →
Continuity (4)
Continuation 18411476 · Jan 12, 2024
Continuation 17225560 · Apr 8, 2021
Provisional Application 63007584 · Apr 9, 2020
Related Publication 20240293173A1 · Sep 5, 2024
References Cited (349)
US 874178A · Forest · 1907 [cited by applicant]
US 3117571A · Fry et al. · 1964 [cited by applicant]
US 3538919A · Meyer · 1970 [cited by applicant]
US 3941121A · Olinger et al. · 1976 [cited by applicant]
US 3987795A · Morrison · 1976 [cited by applicant]
US 4271848A · Turner et al. · 1981 [cited by applicant]
US 4411266A · Cosman · 1983 [cited by applicant]
US 4898169A · Norman et al. · 1990 [cited by applicant]
US 5184625A · Cottone, Jr. et al. · 1993 [cited by applicant]
US 5395383A · Adams et al. · 1995 [cited by applicant]
US 5456662A · Edwards et al. · 1995 [cited by applicant]
US 5562720A · Stern et al. · 1996 [cited by applicant]
US 5575788A · Baker et al. · 1996 [cited by applicant]
US 5588429A · Isaacson et al. · 1996 [cited by applicant]
US 5697536A · Eggers et al. · 1997 [cited by applicant]
US 5697882A · Eggers et al. · 1997 [cited by applicant]
US 5746224A · Edwards · 1998 [cited by applicant]
US 5766605A · Sanders et al. · 1998 [cited by applicant]
US 5800429A · Edwards · 1998 [cited by applicant]
US 5823197A · Edwards · 1998 [cited by applicant]
US 5827277A · Edwards · 1998 [cited by applicant]
US 5836947A · Fleischman et al. · 1998 [cited by applicant]
US 5843026A · Edwards et al. · 1998 [cited by applicant]
US 6033397A · Laufer et al. · 2000 [cited by applicant]
US 6045532A · Eggers et al. · 2000 [cited by applicant]
US 6053172A · Hovda et al. · 2000 [cited by applicant]
US 6063079A · Hovda et al. · 2000 [cited by applicant]
US 6106518A · Wittenberger et al. · 2000 [cited by applicant]
US 6139527A · Laufer et al. · 2000 [cited by applicant]
US 6142991A · Schatzberger · 2000 [cited by applicant]
US 6273886B1 · Edwards et al. · 2001 [cited by applicant]
US 6332880B1 · Yang et al. · 2001 [cited by applicant]
US 6352533B1 · Ellman et al. · 2002 [cited by applicant]
US 6517534B1 · McGovern et al. · 2003 [cited by applicant]
US 6517535B2 · Edwards · 2003 [cited by applicant]
US 6520185B1 · Bommannan et al. · 2003 [cited by applicant]
US 6529756B1 · Phan et al. · 2003 [cited by applicant]
US 6594518B1 · Benaron et al. · 2003 [cited by applicant]
US 6595988B2 · Wittenberger et al. · 2003 [cited by applicant]
US 6626899B2 · Houser et al. · 2003 [cited by applicant]
US 6652548B2 · Evans et al. · 2003 [cited by applicant]
US 6669689B2 · Lehmann et al. · 2003 [cited by applicant]
US 6685648B2 · Flaherty et al. · 2004 [cited by applicant]
US 6746474B2 · Saadat · 2004 [cited by applicant]
US 7195629B2 · Behl et al. · 2007 [cited by applicant]
US 7232458B2 · Saadat · 2007 [cited by applicant]
US 7285119B2 · Stewart et al. · 2007 [cited by applicant]
US 7500985B2 · Saadat · 2009 [cited by applicant]
US 7524318B2 · Young et al. · 2009 [cited by applicant]
US 7608275B2 · Deem et al. · 2009 [cited by applicant]
US 7654997B2 · Makower et al. · 2010 [cited by applicant]
US 7655243B2 · Deem et al. · 2010 [cited by applicant]
US 7758571B2 · Saadat · 2010 [cited by applicant]
US 7771409B2 · Chang et al. · 2010 [cited by applicant]
US 7803150B2 · Chang et al. · 2010 [cited by applicant]
US 8105817B2 · Deem et al. · 2012 [cited by applicant]
US 8133497B2 · Deem et al. · 2012 [cited by applicant]
US 8231613B2 · Baxter et al. · 2012 [cited by applicant]
US 8338164B2 · Deem et al. · 2012 [cited by applicant]
US 8372068B2 · Truckai · 2013 [cited by applicant]
US 8382746B2 · Williams et al. · 2013 [cited by applicant]
US 8460181B2 · Saadat et al. · 2013 [cited by applicant]
US 8463359B2 · Saadat et al. · 2013 [cited by applicant]
US 8512324B2 · Abboud et al. · 2013 [cited by applicant]
US 8636684B2 · Deem et al. · 2014 [cited by applicant]
US 8747401B2 · Gonzalez et al. · 2014 [cited by applicant]
US 8920414B2 · Stone et al. · 2014 [cited by applicant]
US 8936594B2 · Wolf et al. · 2015 [cited by applicant]
US 8939970B2 · Stone et al. · 2015 [cited by applicant]
US 8961391B2 · Deem et al. · 2015 [cited by applicant]
US 8986301B2 · Wolf et al. · 2015 [cited by applicant]
US 8996137B2 · Ackermann et al. · 2015 [cited by applicant]
US 9055965B2 · Chang et al. · 2015 [cited by applicant]
US 9072597B2 · Wolf et al. · 2015 [cited by applicant]
US 9101384B2 · Makower et al. · 2015 [cited by applicant]
US 9179964B2 · Wolf et al. · 2015 [cited by applicant]
US 9179967B2 · Wolf et al. · 2015 [cited by applicant]
US 9179973B2 · Nabutovsky et al. · 2015 [cited by applicant]
US 9233245B2 · Lamensdorf et al. · 2016 [cited by applicant]
US 9237924B2 · Wolf et al. · 2016 [cited by applicant]
US 9333023B2 · Wittenberger · 2016 [cited by applicant]
US 9370649B2 · Chang et al. · 2016 [cited by applicant]
US 9415194B2 · Wolf et al. · 2016 [cited by applicant]
US 9433463B2 · Wolf et al. · 2016 [cited by applicant]
US 9440065B2 · Ackermann et al. · 2016 [cited by applicant]
US 9452010B2 · Wolf et al. · 2016 [cited by applicant]
US 9486278B2 · Wolf et al. · 2016 [cited by applicant]
US 9498278B2 · Couture et al. · 2016 [cited by applicant]
US 9498283B2 · Deem et al. · 2016 [cited by applicant]
US 9526571B2 · Wolf et al. · 2016 [cited by applicant]
US 9649156B2 · Jenson et al. · 2017 [cited by applicant]
US 9655667B2 · Hon · 2017 [cited by applicant]
US 9687288B2 · Saadat · 2017 [cited by applicant]
US 9687296B2 · Wolf et al. · 2017 [cited by applicant]
US 9700707B2 · Deem et al. · 2017 [cited by applicant]
US 9737702B2 · Ackermann et al. · 2017 [cited by applicant]
US 9763723B2 · Saadat · 2017 [cited by applicant]
US 9763743B2 · Lin et al. · 2017 [cited by applicant]
US 9788886B2 · Wolf et al. · 2017 [cited by applicant]
US 9801752B2 · Wolf et al. · 2017 [cited by applicant]
US 9888957B2 · Wolf et al. · 2018 [cited by applicant]
US 9913682B2 · Wolf et al. · 2018 [cited by applicant]
US 9943361B2 · Wolf et al. · 2018 [cited by applicant]
US 10022529B2 · Deem et al. · 2018 [cited by applicant]
US 10028780B2 · Wolf et al. · 2018 [cited by applicant]
US 10028781B2 · Saadat · 2018 [cited by applicant]
US 10052465B2 · Deem et al. · 2018 [cited by applicant]
US 10155108B2 · Ackermann et al. · 2018 [cited by applicant]
US 10159538B2 · Lin et al. · 2018 [cited by applicant]
US 10201687B2 · Saadat · 2019 [cited by applicant]
US 10238861B2 · Ackermann et al. · 2019 [cited by applicant]
US 10252048B2 · Loudin et al. · 2019 [cited by applicant]
US 10265115B2 · Wolf et al. · 2019 [cited by applicant]
US 10307200B2 · Saadat · 2019 [cited by applicant]
US 10335221B2 · Wolf et al. · 2019 [cited by applicant]
US 10363094B2 · Brannan et al. · 2019 [cited by applicant]
US 10376300B2 · Wolf et al. · 2019 [cited by applicant]
US 10398489B2 · Wolf et al. · 2019 [cited by applicant]
US 10448985B2 · Saadat · 2019 [cited by applicant]
US 10456185B2 · Wolf et al. · 2019 [cited by applicant]
US 10456186B1 · Wolf et al. · 2019 [cited by applicant]
US 10485603B2 · Wolf et al. · 2019 [cited by applicant]
US 10588682B2 · Kelly et al. · 2020 [cited by applicant]
US 10610675B2 · Deem et al. · 2020 [cited by applicant]
US 10687883B2 · Aklog et al. · 2020 [cited by applicant]
US 10695557B1 · Townley et al. · 2020 [cited by applicant]
US 10729897B2 · Deem et al. · 2020 [cited by applicant]
US 10894011B2 · Deem et al. · 2021 [cited by applicant]
US 11033318B2 · Wolf et al. · 2021 [cited by applicant]
US 11241271B2 · Wolf et al. · 2022 [cited by applicant]
US 11304746B2 · Wolf et al. · 2022 [cited by applicant]
US 11679077B2 · Deem et al. · 2023 [cited by applicant]
US 11766286B2 · Wolf et al. · 2023 [cited by applicant]
US 11998262B1 · Townley · 2024 [cited by examiner]
US 20020068930A1 · Tasto et al. · 2002 [cited by applicant]
US 20020072742A1 · Schaefer et al. · 2002 [cited by applicant]
US 20020177765A1 · Bowe et al. · 2002 [cited by applicant]
US 20030016085A1 · Yamazaki · 2003 [cited by applicant]
US 20030212394A1 · Pearson et al. · 2003 [cited by applicant]
US 20050080409A1 · Young et al. · 2005 [cited by applicant]
US 20050171536A1 · Phan et al. · 2005 [cited by applicant]
US 20050171574A1 · Rubinsky et al. · 2005 [cited by applicant]
US 20050171582A1 · Matlock · 2005 [cited by applicant]
US 20050171583A1 · Mosher et al. · 2005 [cited by applicant]
US 20050187546A1 · Bek et al. · 2005 [cited by applicant]
US 20050240147A1 · Makower et al. · 2005 [cited by applicant]
US 20050283148A1 · Janssen et al. · 2005 [cited by applicant]
US 20050288730A1 · Deem et al. · 2005 [cited by applicant]
US 20060036237A1 · Davison et al. · 2006 [cited by applicant]
US 20060055942A1 · Krattiger · 2006 [cited by applicant]
US 20060100620A1 · Daniel et al. · 2006 [cited by applicant]
US 20060106375A1 · Werneth et al. · 2006 [cited by applicant]
US 20060116599A1 · Davis · 2006 [cited by applicant]
US 20060149226A1 · McCullagh et al. · 2006 [cited by applicant]
US 20060247683A1 · Danek et al. · 2006 [cited by applicant]
US 20070006975A1 · Corghi · 2007 [cited by applicant]
US 20070031341A1 · DiMauro et al. · 2007 [cited by applicant]
US 20070032786A1 · Francischelli · 2007 [cited by applicant]
US 20070083194A1 · Kunis et al. · 2007 [cited by applicant]
US 20070083195A1 · Werneth et al. · 2007 [cited by applicant]
US 20070093803A1 · Dalbec et al. · 2007 [cited by applicant]
US 20070129760A1 · Demarais et al. · 2007 [cited by applicant]
US 20070173760A1 · Fedenia et al. · 2007 [cited by applicant]
US 20070219600A1 · Gertner et al. · 2007 [cited by applicant]
US 20070233191A1 · Parmer · 2007 [cited by applicant]
US 20070265608A1 · Hernandez · 2007 [cited by applicant]
US 20070287994A1 · Patel · 2007 [cited by applicant]
US 20070299433A1 · Williams et al. · 2007 [cited by applicant]
US 20080021369A1 · Deem et al. · 2008 [cited by applicant]
US 20080154250A1 · Makower et al. · 2008 [cited by applicant]
US 20080287908A1 · Muni et al. · 2008 [cited by applicant]
US 20090198216A1 · Muni et al. · 2009 [cited by applicant]
US 20090306644A1 · Mayse et al. · 2009 [cited by applicant]
US 20090318914A1 · Utley et al. · 2009 [cited by applicant]
US 20100049187A1 · Carlton et al. · 2010 [cited by applicant]
US 20100057048A1 · Eldredge · 2010 [cited by applicant]
US 20100168737A1 · Grunewald · 2010 [cited by applicant]
US 20100204560A1 · Salahieh et al. · 2010 [cited by applicant]
US 20100305715A1 · Mathis et al. · 2010 [cited by applicant]
US 20110004207A1 · Wallace et al. · 2011 [cited by applicant]
US 20110152855A1 · Mayse et al. · 2011 [cited by applicant]
US 20110238057A1 · Moss et al. · 2011 [cited by applicant]
US 20110264086A1 · Ingle · 2011 [cited by applicant]
US 20120078377A1 · Gonzales et al. · 2012 [cited by applicant]
US 20120191003A1 · Garabedian · 2012 [cited by applicant]
US 20120259326A1 · Brannan et al. · 2012 [cited by applicant]
US 20120323214A1 · Shantha · 2012 [cited by applicant]
US 20120323227A1 · Wolf et al. · 2012 [cited by applicant]
US 20120323232A1 · Wolf et al. · 2012 [cited by applicant]
US 20130018367A1 · Wu et al. · 2013 [cited by applicant]
US 20130123778A1 · Richardson et al. · 2013 [cited by applicant]
US 20130158475A1 · Xia et al. · 2013 [cited by applicant]
US 20130165916A1 · Mathur et al. · 2013 [cited by applicant]
US 20130172877A1 · Subramaniam et al. · 2013 [cited by applicant]
US 20130178910A1 · Azamian et al. · 2013 [cited by applicant]
US 20130253387A1 · Bonutti et al. · 2013 [cited by applicant]
US 20130253389A1 · Juto et al. · 2013 [cited by applicant]
US 20130282084A1 · Mathur et al. · 2013 [cited by applicant]
US 20130289552A1 · Young · 2013 [cited by applicant]
US 20140005706A1 · Gelfand et al. · 2014 [cited by applicant]
US 20140018792A1 · Gang et al. · 2014 [cited by applicant]
US 20140025069A1 · Willard et al. · 2014 [cited by applicant]
US 20140074091A1 · Arya et al. · 2014 [cited by applicant]
US 20140100557A1 · Bohner et al. · 2014 [cited by applicant]
US 20140114233A1 · Deem et al. · 2014 [cited by applicant]
US 20140180196A1 · Stone et al. · 2014 [cited by applicant]
US 20140200581A1 · Aluru et al. · 2014 [cited by applicant]
US 20140243793A1 · Morriss et al. · 2014 [cited by applicant]
US 20140276752A1 · Wang et al. · 2014 [cited by applicant]
US 20140303665A1 · Gerrans et al. · 2014 [cited by applicant]
US 20150006606A1 · Fleury et al. · 2015 [cited by applicant]
US 20150018818A1 · Willard et al. · 2015 [cited by applicant]
US 20150031946A1 · Saadat et al. · 2015 [cited by applicant]
US 20150066006A1 · Srivastava · 2015 [cited by applicant]
US 20150112321A1 · Cadouri · 2015 [cited by applicant]
US 20150119881A1 · Bagley et al. · 2015 [cited by applicant]
US 20150150624A1 · Petersohn · 2015 [cited by applicant]
US 20150164571A1 · Saadat · 2015 [cited by applicant]
US 20150182282A1 · Zemel et al. · 2015 [cited by applicant]
US 20150202003A1 · Wolf et al. · 2015 [cited by applicant]
US 20150257754A1 · Weng et al. · 2015 [cited by applicant]
US 20150257824A1 · Mauch · 2015 [cited by applicant]
US 20150257825A1 · Kelly et al. · 2015 [cited by applicant]
US 20150265812A1 · Lalonde · 2015 [cited by applicant]
US 20150289750A1 · Stigall et al. · 2015 [cited by applicant]
US 20150297282A1 · Cadouri · 2015 [cited by applicant]
US 20150313669A1 · Darmos et al. · 2015 [cited by applicant]
US 20150351836A1 · Prutchi · 2015 [cited by applicant]
US 20160008053A1 · Mathur et al. · 2016 [cited by applicant]
US 20160015450A1 · Wolf et al. · 2016 [cited by applicant]
US 20160045277A1 · Lin et al. · 2016 [cited by applicant]
US 20160120598A1 · Brink et al. · 2016 [cited by applicant]
US 20160128767A1 · Azamian et al. · 2016 [cited by applicant]
US 20160250474A1 · Stack et al. · 2016 [cited by applicant]
US 20160287315A1 · Wolf et al. · 2016 [cited by applicant]
US 20160331459A1 · Townley et al. · 2016 [cited by applicant]
US 20160354136A1 · Saadat · 2016 [cited by applicant]
US 20170071494A1 · Solis et al. · 2017 [cited by applicant]
US 20170095252A1 · Smith et al. · 2017 [cited by applicant]
US 20170095288A1 · Wolf et al. · 2017 [cited by applicant]
US 20170151014A1 · Perfler · 2017 [cited by applicant]
US 20170209199A1 · Wolf et al. · 2017 [cited by applicant]
US 20170215950A1 · Gross et al. · 2017 [cited by applicant]
US 20170215952A1 · Nair · 2017 [cited by applicant]
US 20170231474A1 · Saadat et al. · 2017 [cited by applicant]
US 20170231651A1 · Dinger et al. · 2017 [cited by applicant]
US 20170245924A1 · Wolf et al. · 2017 [cited by applicant]
US 20170252089A1 · Hester et al. · 2017 [cited by applicant]
US 20170252100A1 · Wolf et al. · 2017 [cited by applicant]
US 20170266422A1 · Deem et al. · 2017 [cited by applicant]
US 20170312021A1 · Pilcher et al. · 2017 [cited by applicant]
US 20180042471A1 · Chandler et al. · 2018 [cited by applicant]
US 20180049802A1 · Yang et al. · 2018 [cited by applicant]
US 20180063678A1 · Zhu et al. · 2018 [cited by applicant]
US 20180078327A1 · Lin et al. · 2018 [cited by applicant]
US 20180103994A1 · Fox et al. · 2018 [cited by applicant]
US 20180125560A1 · Saadat et al. · 2018 [cited by applicant]
US 20180133460A1 · Townley et al. · 2018 [cited by applicant]
US 20180153375A1 · Saadat et al. · 2018 [cited by applicant]
US 20180161577A1 · Goedeke et al. · 2018 [cited by applicant]
US 20180168503A1 · Waldhauser et al. · 2018 [cited by applicant]
US 20180169414A1 · Goedeke et al. · 2018 [cited by applicant]
US 20180177542A1 · Wolf et al. · 2018 [cited by applicant]
US 20180177546A1 · Dinger et al. · 2018 [cited by applicant]
US 20180185085A1 · Wolf et al. · 2018 [cited by applicant]
US 20180228533A1 · Wolf et al. · 2018 [cited by applicant]
US 20180317993A1 · Saadat · 2018 [cited by applicant]
US 20180317997A1 · Dinger et al. · 2018 [cited by applicant]
US 20180344378A1 · Wolf et al. · 2018 [cited by applicant]
US 20180344411A1 · Fahey et al. · 2018 [cited by applicant]
US 20190069949A1 · Vrba et al. · 2019 [cited by applicant]
US 20190076185A1 · Dinger et al. · 2019 [cited by applicant]
US 20190083157A1 · Saadat · 2019 [cited by applicant]
US 20190175242A1 · Wolf et al. · 2019 [cited by applicant]
US 20190223944A1 · Coates · 2019 [cited by applicant]
US 20190231409A1 · Wolf et al. · 2019 [cited by applicant]
US 20190231429A1 · Townley et al. · 2019 [cited by applicant]
US 20190239953A1 · Townley et al. · 2019 [cited by applicant]
US 20190239954A1 · Townley et al. · 2019 [cited by applicant]
US 20190239955A1 · Townley et al. · 2019 [cited by applicant]
US 20190239956A1 · Townley et al. · 2019 [cited by applicant]
US 20190239957A1 · Townley et al. · 2019 [cited by applicant]
US 20190282289A1 · Wolf et al. · 2019 [cited by applicant]
US 20190314620A1 · Chang et al. · 2019 [cited by applicant]
US 20200078134A1 · Loyd et al. · 2020 [cited by applicant]
US 20200086112A1 · Townley et al. · 2020 [cited by applicant]
US 20200107882A1 · Townley et al. · 2020 [cited by applicant]
US 20200129223A1 · Angeles et al. · 2020 [cited by applicant]
US 20200289185A1 · Forsyth et al. · 2020 [cited by applicant]
US 20210315627A1 · Babkin et al. · 2021 [cited by applicant]
EP 2929852A1 · 2015 [cited by applicant]
JP 2001120565A · 2001 [cited by applicant]
JP 2001526077A · 2001 [cited by applicant]
JP 2007537784A · 2007 [cited by applicant]
JP 2009538641A · 2009 [cited by applicant]
JP 2012143573A · 2012 [cited by applicant]
JP 2015507964A · 2015 [cited by applicant]
JP 2018515314A · 2018 [cited by applicant]
WO 9410921A1 · 1994 [cited by applicant]
WO 0117450A1 · 2001 [cited by applicant]
WO 2007008954A2 · 2007 [cited by applicant]
WO 2009154456A1 · 2009 [cited by applicant]
WO 2010077980A1 · 2010 [cited by applicant]
WO 2015013252A1 · 2015 [cited by applicant]
WO 2015048806A2 · 2015 [cited by applicant]
WO 2016134264A1 · 2016 [cited by applicant]
WO 2016183337A2 · 2016 [cited by applicant]
WO 2018087601A1 · 2018 [cited by applicant]
WO 2021205230A1 · 2021 [cited by applicant]
WO 2021205231A1 · 2021 [cited by applicant]
WO 2021260435A1 · 2021 [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K150637, dated Oct. 23, 2015 (8 pages). [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K161994, dated Aug. 19, 2016 (6 pages). [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K162810, dated Dec. 9, 2016 (7 pages). [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K172529, dated Nov. 2, 2017 (7 pages). [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K192471, dated Sep. 9, 2019 (7 pages). [cited by applicant]
Aerin Medical FDA 510(k) Summary—510(k) No. K200300, dated Mar. 13, 2020 (6 pages). [cited by applicant]
Annotated Perfler Fig 11 (2022). [cited by applicant]
Anonymous: Flexible electronics—Wikipedia, Aug. 8, 202, pp. 1-9. [cited by applicant]
Arora, 1980, Cryodestruction of Vidian Nerve Branches, Indian Journal of Otolaryngology, 32(3):80-82. [cited by applicant]
Chen, 2005, Radiofrequency treatment of nasal posterior-under nerve ethmoidal nerve and infraturbinal for perennial allergic rhinitis under nasal endoscope, China Journal of Endoscopy, 11(3):239-243. [cited by applicant]
Fang, 2005, Nasal endoscopy combined with multiple radiofrequency for perennial allergic rhinitis, J. First Mil. Medic Univ., 25(7):876-877. [cited by applicant]
Horesh, 2006, Some novel approaches in modelling and image reconstruction for multi-frequency Electrical Impedance Tomography of the human brain, Thesis (Ph.D.)—University of London, University College London (United Ki… [cited by applicant]
Ikeda, 2008, Effect of resection of the posterior nasal nerve on functional and morphological changes in the inferior turbinate mucosa, Acta Oto-Laryngologica, 128, pp. 1337-1341. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/032132, filed May 12, 2016, Applicant: National University of Ireland, Galway, Date of Mailing: Nov. 14, 2016, 26 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2017/001541, date of mailing: Apr. 3, 2018, 15 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2019/001298, date of mailing May 12, 2020, 15 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2020/000544, date of mailing Jan. 11, 2021, 15 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000234, date of mailing: Aug. 6, 2021, 14 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000243, date of mailing: Aug. 25, 2021, 15 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000597, date of mailing: Jan. 22, 2022, 18 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000667, date of mailing: Feb. 2, 2022, 17 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000699, date mailing: Feb. 4, 2022, 28 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2021/000700, date of mailing: Apr. 4, 2022, 20 pages. [cited by applicant]
Kanaya, 2009, Endoscopic posterior nasal neurectomy: an alternative to Vidian neurectomy, Clinical and Experimental Allergy Reviews, pp. 24-27. [cited by applicant]
Kikawada, 2007, Endoscopic posterior nasal neurectomy: An alternative to vidian neurectomy, Operative Techniques in Otolaryngology, 18(4), 5 pages. [cited by applicant]
Kobayashi, 2012, Resection of peripheral branches of the posterior nasal nerve compared to conventional posterior neuectomy in severe allergic rhinitis, Auris Nasus Larynx, 39 (2012):593-596. [cited by applicant]
Kong, 2005, Low-temperature plasma ablation of inferior turbinate for the treatment of perennial allergic rhinitis, 19:5 J Clin Otorhinolaryngol (China), 19:5:214. [cited by applicant]
Lane, 2004, Nasal anatomy and physiology, Facial Plast Surg Clin North Am., 12(4):387-395. [cited by applicant]
Lee, 2003, Sampling and Reconstruction, In: Structure and Interpretation of Singals and Systems, Reading, MA: Addison-Wesley, ISBN: 0-201-74551-8, Pearson Education, Inc., pp. 373-392. [cited by applicant]
Liang, 1999, Radiofrequency treatment of ethmoidal nerve with allergic rhinitis under nasal endoscopy, J. Clin Otorhinolaryngol, 13(8):341-342. [cited by applicant]
Lin, 2003, Radiofrequency for the treatment of allergic rhinits refactory to medical therapy, The Laryngoscope, 113, pp. 673-678. [cited by applicant]
Lin, 2010, Long-term results of radiofrequency turbinoplasty for allergic rhinits refactor to medical therapy, Arch Otolaryngol Head Neck Surg, 136(9) 4 pages. [cited by applicant]
Min, 2015, Impedance Detection, In: Li, D. (eds) Encyclopedia of Microfluidics and Nanofluidics, Springer, New York, NY, https://doi.org/10.1007/978-1-4614-5491-5_1783, pp. 1333-1472. [cited by applicant]
Neubauer, 2022, Endothelial cells and coagulation, Cell Tissue Res, 387:391-398. [cited by applicant]
Ozenbeger, 1970, Cryosurgery in chronic rhinitis, The Laryngoscope, vol. 8, issue 5, pp. 723-734. [cited by applicant]
Ozenberger, 1973, Cryosurgery for the treatment of chronic rhinitis, The Laryngoscope, vol. 83, issue 4, pp. 508-516. [cited by applicant]
Paterno, 2009, Frequency-dpmain reconstruction of singals in electrical bioimpedance spectroscopy, Med Biol Eng Comput, 47(10):1093-1102. [cited by applicant]
Yang, 2014, Electrical Impedance Tomography: Algorithms and Application, University of Bath, 143 pages. [cited by applicant]